Yayın: Effect of castration procedure on the pharmacokinetics of meloxicam in goat kids
| dc.contributor.author | Tekeli, Ibrahim Ozan | |
| dc.contributor.author | Turk, Erdinc | |
| dc.contributor.author | Durna Corum, Duygu | |
| dc.contributor.author | Corum, Orhan | |
| dc.contributor.author | Uney, Kamil | |
| dc.date.accessioned | 2026-01-04T14:08:45Z | |
| dc.date.issued | 2020-05-18 | |
| dc.description.abstract | AbstractThe aim of this study was to determine the changes in the pharmacokinetics of meloxicam in goat kids who were castrated following the administration of xylazine. Six goat kids were used for the study. The study was performed in two periods according to a longitudinal study, with a 15‐day washout period between periods. In the first period (Control group), 1 mg/kg meloxicam was administered by i.v. route to kids. In the second period (Castration group), the kids were sedated with 0.3 mg/kg xylazine and castration was performed following meloxicam administration. Plasma meloxicam concentration was analyzed using HPLC‐UV, and pharmacokinetic parameters were calculated by noncompartmental model. In the control group following the administration of meloxicam, mean elimination half‐life (t1/2ʎz), area under the concentration–time curve (AUC0−∞), total body clearance (ClT), and volume of distribution at steady‐state (Vdss) were 13.50 ± 0.62 hr, 41.10 ± 2.86 hr µg/ml, 24.43 ± 1.75 ml hr−1 kg−1, and 0.45 ± 0.03 L/kg, respectively. In the castration group, the t1/2ʎz of meloxicam prolonged, AUC0−∞ increased, and ClT and Vdss decreased. In conclusion, the excretion of meloxicam from the body slowed and the t1/2ʎz was prolonged in the castrated goat kids following xylazine administration. However, there is a need to determine the pharmacodynamics of meloxicam in castrated goat kids. | |
| dc.description.uri | https://doi.org/10.1111/jvp.12872 | |
| dc.description.uri | https://pubmed.ncbi.nlm.nih.gov/32420638 | |
| dc.description.uri | https://dx.doi.org/10.1111/jvp.12872 | |
| dc.identifier.doi | 10.1111/jvp.12872 | |
| dc.identifier.eissn | 1365-2885 | |
| dc.identifier.endpage | 434 | |
| dc.identifier.issn | 0140-7783 | |
| dc.identifier.openaire | doi_dedup___::1f1d118423231a276754c2c5f8645d51 | |
| dc.identifier.orcid | 0000-0002-6845-2279 | |
| dc.identifier.orcid | 0000-0003-1567-991x | |
| dc.identifier.orcid | 0000-0003-3168-2510 | |
| dc.identifier.orcid | 0000-0002-8674-4873 | |
| dc.identifier.pubmed | 32420638 | |
| dc.identifier.scopus | 2-s2.0-85084844948 | |
| dc.identifier.startpage | 429 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12597/37972 | |
| dc.identifier.volume | 43 | |
| dc.identifier.wos | 000533346700001 | |
| dc.language.iso | eng | |
| dc.publisher | Wiley | |
| dc.relation.ispartof | Journal of Veterinary Pharmacology and Therapeutics | |
| dc.rights | CLOSED | |
| dc.subject | Male | |
| dc.subject | Area Under Curve | |
| dc.subject | Goats | |
| dc.subject | Anti-Inflammatory Agents, Non-Steroidal | |
| dc.subject | Animals | |
| dc.subject | Longitudinal Studies | |
| dc.subject | Meloxicam | |
| dc.subject | Orchiectomy | |
| dc.subject | Half-Life | |
| dc.subject.sdg | 3. Good health | |
| dc.title | Effect of castration procedure on the pharmacokinetics of meloxicam in goat kids | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.api.response | {"authors":[{"fullName":"Ibrahim Ozan Tekeli","name":"Ibrahim Ozan","surname":"Tekeli","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0002-6845-2279"},"provenance":null}},{"fullName":"Erdinc Turk","name":"Erdinc","surname":"Turk","rank":2,"pid":null},{"fullName":"Duygu Durna Corum","name":"Duygu","surname":"Durna Corum","rank":3,"pid":{"id":{"scheme":"orcid","value":"0000-0003-1567-991x"},"provenance":null}},{"fullName":"Orhan Corum","name":"Orhan","surname":"Corum","rank":4,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3168-2510"},"provenance":null}},{"fullName":"Kamil Uney","name":"Kamil","surname":"Uney","rank":5,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8674-4873"},"provenance":null}}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Male"},"provenance":null},{"subject":{"scheme":"FOS","value":"0403 veterinary science"},"provenance":null},{"subject":{"scheme":"keyword","value":"Area Under Curve"},"provenance":null},{"subject":{"scheme":"keyword","value":"Goats"},"provenance":null},{"subject":{"scheme":"keyword","value":"Anti-Inflammatory Agents, Non-Steroidal"},"provenance":null},{"subject":{"scheme":"FOS","value":"0402 animal and dairy science"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"Longitudinal Studies"},"provenance":null},{"subject":{"scheme":"FOS","value":"04 agricultural and veterinary sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Meloxicam"},"provenance":null},{"subject":{"scheme":"keyword","value":"Orchiectomy"},"provenance":null},{"subject":{"scheme":"keyword","value":"Half-Life"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null}],"mainTitle":"Effect of castration procedure on the pharmacokinetics of meloxicam in goat kids","subTitle":null,"descriptions":["<jats:title>Abstract</jats:title><jats:p>The aim of this study was to determine the changes in the pharmacokinetics of meloxicam in goat kids who were castrated following the administration of xylazine. Six goat kids were used for the study. The study was performed in two periods according to a longitudinal study, with a 15‐day washout period between periods. In the first period (Control group), 1 mg/kg meloxicam was administered by i.v. route to kids. In the second period (Castration group), the kids were sedated with 0.3 mg/kg xylazine and castration was performed following meloxicam administration. Plasma meloxicam concentration was analyzed using HPLC‐UV, and pharmacokinetic parameters were calculated by noncompartmental model. In the control group following the administration of meloxicam, mean elimination half‐life (<jats:italic>t</jats:italic><jats:sub>1/2</jats:sub><jats:italic><jats:sub>ʎz</jats:sub></jats:italic>), area under the concentration–time curve (AUC<jats:sub>0−∞</jats:sub>), total body clearance (Cl<jats:sub>T</jats:sub>), and volume of distribution at steady‐state (<jats:italic>V</jats:italic><jats:sub>dss</jats:sub>) were 13.50 ± 0.62 hr, 41.10 ± 2.86 hr µg/ml, 24.43 ± 1.75 ml hr<jats:sup>−1</jats:sup> kg<jats:sup>−1</jats:sup>, and 0.45 ± 0.03 L/kg, respectively. In the castration group, the <jats:italic>t</jats:italic><jats:sub>1/2</jats:sub><jats:italic><jats:sub>ʎz</jats:sub></jats:italic> of meloxicam prolonged, AUC<jats:sub>0−∞</jats:sub> increased, and Cl<jats:sub>T</jats:sub> and <jats:italic>V</jats:italic><jats:sub>dss</jats:sub> decreased. In conclusion, the excretion of meloxicam from the body slowed and the <jats:italic>t</jats:italic><jats:sub>1/2</jats:sub><jats:italic><jats:sub>ʎz</jats:sub></jats:italic> was prolonged in the castrated goat kids following xylazine administration. However, there is a need to determine the pharmacodynamics of meloxicam in castrated goat kids.</jats:p>"],"publicationDate":"2020-05-18","publisher":"Wiley","embargoEndDate":null,"sources":["Crossref"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_14cb","label":"CLOSED","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Journal of Veterinary Pharmacology and Therapeutics","issnPrinted":"0140-7783","issnOnline":"1365-2885","issnLinking":null,"ep":"434","iss":null,"sp":"429","vol":"43","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::1f1d118423231a276754c2c5f8645d51","originalIds":["10.1111/jvp.12872","50|doiboost____|1f1d118423231a276754c2c5f8645d51","32420638","3026471327"],"pids":[{"scheme":"doi","value":"10.1111/jvp.12872"},{"scheme":"pmid","value":"32420638"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":13,"influence":3.054499e-9,"popularity":1.1706818e-8,"impulse":9,"citationClass":"C4","influenceClass":"C5","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1111/jvp.12872"}],"license":"Wiley Online Library User Agreement","type":"Article","urls":["https://doi.org/10.1111/jvp.12872"],"publicationDate":"2020-05-18","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"32420638"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1111/jvp.12872"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/32420638"],"publicationDate":"2021-06-02","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"mag_id","value":"3026471327"},{"scheme":"doi","value":"10.1111/jvp.12872"}],"type":"Article","urls":["https://dx.doi.org/10.1111/jvp.12872"],"refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false} | |
| local.import.source | OpenAire | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus | |
| local.indexed.at | PubMed |
